We hereby submit outcome of Board Meeting held on August 14, 2025.
Awaiting price reaction for this filing.
The Board of Sarda Proteins Ltd approved the unaudited financial results for the quarter ended June 30, 2025, which were subject to a limited review by statutory auditor S K Agarwal & Associates (unqualified report). Revenue from operations fell sharply to Rs. 1,095.46 lakhs from Rs. 2,419.10 lakhs in the same quarter last year, a decline of about 55% year-on-year. Total expenses stood at Rs. 1,144.88 lakhs versus Rs. 2,417.15 lakhs, but with much lower revenue, the company slipped into a pre-tax and post-tax loss of Rs. 49.34 lakhs compared to a small profit of Rs. 0.51 lakhs in Q1 FY25. Basic and diluted EPS turned negative at Rs. (2.86) versus Rs. 0.03 in the year-ago quarter. No investor complaints were received during the quarter.
A steep revenue drop combined with a swing to losses is negative for shareholders and signals weak operating performance in Q1 FY26. Investors should watch whether the decline is seasonal or reflects deeper demand or pricing issues, as the stock could see short-term pressure on results day.